Target prediction and pathway enrichment showed that the bioactive compounds, muscone and taurochenodeoxycholic acid, target ERBB2 through five signal pathways (pathways in cancer, prostate cancer, proteoglycans in cancer, focal adhesion, and bladder cancer) to inhibit the growth of liver cancer cells. Here, ERBB2 is linked to prostate carcinoma.